Journal article : Letter
Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown
- Abstract:
- Several reports suggest autoantibody-associated neurologic conditions, such as autoimmune encephalitis and myelin-oligodendrocyte glycoprotein (MOG) antibody–associated diseases, may be triggered by the COVID-19 pandemic and associated vaccinations.1,2 Conversely, public health measures, including lockdowns, might reduce the incidence of immune-mediated neurologic disorders through fewer antecedent infective agents.3 To understand real-world implications of COVID-19–instigated public health measures on the most common autoantibody-mediated neurologic conditions, we compared positivity rates of the most prevalent neuroglial surface autoantibodies between prepandemic (2019) and postpandemic (2020) time points. We hypothesized that lockdown measures may reduce the rates of neurologic autoantibody positivity.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 173.9KB, Terms of use)
-
- Publisher copy:
- 10.1001/jamaneurol.2022.5346
Authors
- Publisher:
- American Medical Association
- Journal:
- JAMA Neurology More from this journal
- Volume:
- 80
- Issue:
- 4
- Pages:
- 419-420
- Publication date:
- 2023-02-13
- Acceptance date:
- 2022-12-09
- DOI:
- EISSN:
-
2168-6157
- ISSN:
-
2168-6149
- Language:
-
English
- Keywords:
- Subtype:
-
Letter
- Pubs id:
-
1314609
- Local pid:
-
pubs:1314609
- Deposit date:
-
2022-12-11
Terms of use
- Copyright holder:
- American Medical Association
- Copyright date:
- 2023
- Rights statement:
- © 2023 American Medical Association. All rights reserved.
- Notes:
-
This research was funded in whole or in part by a senior clinical fellowship from the Medical Research Council [MR/V007173/1], Wellcome Trust Fellowship [104079/Z/14/Z], BMA Research Grants- Vera Down grant (2013) and Margaret Temple (2017), Epilepsy Research UK (P1201), the Fulbright UK-US commission (MS-Society research award) and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission.
This is the accepted manuscript version of the article. The final version is available from American Medical Association at https://doi.org/10.1001/jamaneurol.2022.5346
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record